Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"The Lancet. Oncology"
topic_facet:"EC 2.7.10.1"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22The+Lancet.+Oncology%22&filter%5B%5D=topic_facet%3A%22EC+2.7.10.1%22&lookfor=%22Antibodies%2C+Monoclonal%2C+Humanized%22&type=Subject
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22The+Lancet.+Oncology%22&filter%5B%5D=topic_facet%3A%22EC+2.7.10.1%22&lookfor=%22Antibodies%2C+Monoclonal%2C+Humanized%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=journalStr%3A%22The+Lancet.+Oncology%22&filter%5B%5D=topic_facet%3A%22EC+2.7.10.1%22&lookfor=%22Antibodies%2C+Monoclonal%2C+Humanized%22&type=Subject
PubPharm (114)
1
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3) : a multicentre, single-arm, phase 2 study
enthalten in:
The Lancet. Oncology
| 2024
von
van der Voort, A.
|
Louis, F.
|
van Ramshorst, M.
| +52
Wird geladen...
2
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01) : primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
enthalten in:
The Lancet. Oncology
| 2024
von
Smit, E.
|
Felip, E.
|
Uprety, D.
| +17
Wird geladen...
3
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02) : primary and updated analyses from a single-arm, phase 2 study
enthalten in:
The Lancet. Oncology
| 2023
von
Van Cutsem, E.
|
di Bartolomeo, M.
|
Smyth, E.
| +13
Wird geladen...
4
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER) : a multicentre, open-label, phase 2 study
enthalten in:
The Lancet. Oncology
| 2023
von
Strickler, J.
|
Cercek, A.
|
Siena, S.
| +84
Wird geladen...
5
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31) : first interim results from a randomised, double-blind, multicentre, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2022
von
Lu, S.
|
Wu, L.
|
Jian, H.
| +24
CommentIn: Lancet Oncol. 2022 Sep;23(9):1113-1114. - PMID 35908559
Wird geladen...
6
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway) : a multicentre, open-label, phase 2a, multiple basket study
enthalten in:
The Lancet. Oncology
| 2021
von
Javle, M.
|
Borad, M.
|
Azad, N.
| +16
CommentIn: Lancet Oncol. 2021 Sep;22(9):1204-1206. - PMID 34478661
Wird geladen...
7
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma : an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
enthalten in:
The Lancet. Oncology
| 2021
von
Sacco, A.
|
Chen, R.
|
Worden, F.
| +16
Wird geladen...
8
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain) : a multicentre, randomised, open-label, non-comparative, phase 2 trial
enthalten in:
The Lancet. Oncology
| 2021
von
Pérez-García, J.
|
Gebhart, G.
|
Ruiz Borrego, M.
| +20
CommentIn: Future Oncol. 2022 Oct;18(33):3677-3688. - PMID 36300423
Wird geladen...
9
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01) : a multicentre, open-label, phase 2 trial
enthalten in:
The Lancet. Oncology
| 2021
von
Siena, S.
|
Di Bartolomeo, M.
|
Raghav, K.
| +22
CommentIn: Lancet Oncol. 2021 Jun;22(6):739-741. - PMID 33961794
Wird geladen...
10
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa) : a randomised, open-label, multicentre, non-inferiority, phase 3 study
enthalten in:
The Lancet. Oncology
| 2021
von
Tan, A.
|
Im, S.
|
Mattar, A.
| +15
CommentIn: Lancet Oncol. 2021 Jan;22(1):5-6. - PMID 33357419
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Zeitschrift: The Lancet. Oncology
Filter aufheben
Thema: EC 2.7.10.1
Medienart
114
Aufsätze
101
E-Artikel
101
E-Ressourcen
13
Gedruckte Aufsätze
Zeitschriftentitel
The Lancet. Oncology
Thema
114
Antibodies, Monoclonal, Humanized
EC 2.7.10.1
96
Journal Article
82
Receptor, ErbB-2
69
P188ANX8CK
69
Trastuzumab
67
Research Support, Non-U.S. Gov't
55
ERBB2 protein, human
52
Multicenter Study
45
Randomized Controlled Trial
40
Antibodies, Monoclonal
35
Antineoplastic Agents
33
Clinical Trial, Phase III
27
Clinical Trial, Phase II
23
ErbB Receptors
20
K16AIQ8CTM
20
pertuzumab
17
Biomarkers, Tumor
16
2S9ZZM9Q9V
16
Bevacizumab
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
17
2020-
78
2010-2019
16
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
114
Englisch
Haven't found what you're looking for?
Wird geladen...